|Bid||10.21 x 1000|
|Ask||10.59 x 900|
|Day's Range||10.26 - 10.76|
|52 Week Range||2.85 - 15.85|
|Beta (5Y Monthly)||2.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.93|
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the first patient successfully enrolled to the study.
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner, will be presenting virtually at the upcoming LD Micro Invitational XI.
We can readily understand why investors are attracted to unprofitable companies. For example, Kazia Therapeutics...